Inhibition of glioma cell proliferation and invasion by neural stem cell factor and ex vivo gene therapy.

神经干细胞因子和离体基因治疗抑制胶质瘤细胞增殖和侵袭。

基本信息

  • 批准号:
    15591521
  • 负责人:
  • 金额:
    $ 2.3万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2003
  • 资助国家:
    日本
  • 起止时间:
    2003 至 2004
  • 项目状态:
    已结题

项目摘要

Neural stem cells have unique differentiation-, proliferation-, and motility properties. To investigate whether they secrete factors that interfere with the proliferation and motility of glioma cells, we grew glioma cells in conditioned medium obtained from cultures of neurospheres including neural stem cells (NSC/CM) isolated from embryonic mouse brain. NSPC/CM contained factor(s) that inhibited the proliferation of glioma cells by 28-87%. NSPC/CM was found to contain another factor(s) that inhibited the motility of glioma cells by Boyden chamber assay. Filter-fractionation of NSPC/CM revealed that the 50,000 - 100,000 nominal molecular weight limit (NMWL) fraction contained the inhibitory activity of both cell-proliferation and -motility. Purification of the factor(s) by column chromatography was failed. Inhibition of cell-motility by NSPC/CM was also detected in the organotypic brain slice culture method using an inverted confocal laser scanning microscope. On the basis of these observations we transplanted 203G glioma cells and/or NSPC into the intrathecal space of the cisterna magna of mice in vivo. Mice transplanted with both 203G and NSPC survived significantly longer than did mice transplanted only with 203G. We concluded that NSPC secrete factor(s) that may control glioma cell proliferation and invasion. NCSs have been shown to exhibit potent tropism for disseminating glioma cells in vivo. Therefore we established NSCs which engineered to secrete interleukin 12 with GFP expressing vector, and the expression of interleukin 12 from NSCs was detected. Ex vivo gene therapy with NSCs may be a new treatment modality for the malignant glioma.
神经干细胞具有独特的分化、增殖和运动特性。为了研究它们是否分泌干扰胶质瘤细胞增殖和运动的因子,我们在条件培养基中培养胶质瘤细胞,条件培养基来自从胚胎小鼠脑分离的神经干细胞(NSC/CM)和神经球。NSPC/CM含有抑制胶质瘤细胞增殖28-87%的因子。通过Boyden室实验发现NSPC/CM含有另一种抑制胶质瘤细胞运动的因子。NSPC/CM的过滤分馏法发现,5万- 10万标称分子量(NMWL)的组分具有抑制细胞增殖和细胞运动的活性。用柱层析纯化因子失败。倒置共聚焦激光扫描显微镜还检测了NSPC/CM在器官型脑切片培养方法中对细胞运动的抑制作用。在此基础上,我们将203G胶质瘤细胞和/或NSPC移植到小鼠体内大池鞘内腔。同时移植了203G和NSPC的小鼠比只移植了203G的小鼠存活时间明显更长。我们认为NSPC分泌的因子可能控制胶质瘤细胞的增殖和侵袭。ncs已被证明具有在体内传播胶质瘤细胞的强向性。因此,我们利用GFP表达载体构建了能分泌白细胞介素12的NSCs,并检测了NSCs中白细胞介素12的表达。神经干细胞体外基因治疗可能是恶性胶质瘤的一种新的治疗方式。

项目成果

期刊论文数量(35)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Inhibition of glioma cell proliferation by neural stem cell factor.
神经干细胞因子抑制神经胶质瘤细胞增殖。
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Jiang Z.;Liu Z.;Kato S.;Suzuki M.;Goldbrunner RH et al.;Bhattacharjee AK;Tsuyoshi Suzuki;Kouichi Wada;Tsuyoshi Suzuki
  • 通讯作者:
    Tsuyoshi Suzuki
Yasunori Fujimoto: "Stereotactic radiofrequency ablation for sessile hypothalamic hamartoma with an image fusion technique"Acta Neurochir (Wien). 145. 687-700 (2003)
Yasunori Fujimoto:“采用图像融合技术对无蒂下丘脑错构瘤进行立体定向射频消融”Acta Neurochir(维也纳)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
泉本 修一: "悪性リンパ腫に対するMTX大量化学療法:脳腫瘍の最新医療"先端医療技術研究所. 164-168 (2003)
Shuichi Izumimoto:“MTX高剂量化疗治疗恶性淋巴瘤:脑肿瘤的最新治疗方法”先进医疗技术研究所164-168(2003)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Fiber-tracking does not accurately estimate size of fiber bundle in pathological condition: initial neurosurgical experience using neuronavigation and subcortical white matter stimulation
  • DOI:
    10.1016/j.neuroimage.2004.07.076
  • 发表时间:
    2005-04-01
  • 期刊:
  • 影响因子:
    5.7
  • 作者:
    Kinoshita, M;Yamada, K;Yoshimine, T
  • 通讯作者:
    Yoshimine, T
Manabu Kinoshita: "Primary malignant lymphoma of the trigeminal region treated with rapid infusion of high-dose MTX and radiation case report and review of the literature"Surgical Neurology. 60. 343-348 (2003)
木下学:“大剂量MTX快速输注加放射治疗三叉神经区原发性恶性淋巴瘤病例报告及文献综述”《神经外科》。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

IZUMOTO Shuichi其他文献

IZUMOTO Shuichi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('IZUMOTO Shuichi', 18)}}的其他基金

Investigation of the immunotherapy targeting WT1 against grade 2/3 glioma and its promoting and inhibiting mechanism in the brain.
WT1针对2/3级胶质瘤的免疫治疗及其脑内促进和抑制机制的研究。
  • 批准号:
    17K10881
  • 财政年份:
    2017
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Combined WT1 vaccine immunotherapy and targeted chemotherapy against metastatic brain tumor
WT1疫苗免疫治疗与靶向化疗联合治疗转移性脑肿瘤
  • 批准号:
    26462195
  • 财政年份:
    2014
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigation of the immunotherapy targeting WT1 combined with chemotherapy against newly diagnosed malignant glioma.
WT1靶向免疫治疗联合化疗治疗初诊恶性胶质瘤的研究
  • 批准号:
    20390384
  • 财政年份:
    2008
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Induction and characterization of WT1-specific Th1-type CD4(+) T cells to develop WT1 immunotherapy against malignant gliomas.
WT1 特异性 Th1 型 CD4( ) T 细胞的诱导和表征,以开发针对恶性神经胶质瘤的 WT1 免疫疗法。
  • 批准号:
    19659366
  • 财政年份:
    2007
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Exploratory Research
Development of blood-brain barrier permeable TAT chimera Interferon-β for the treatment of malignant gliomas.
开发血脑屏障可渗透性TAT嵌合体干扰素-β用于治疗恶性胶质瘤。
  • 批准号:
    17591511
  • 财政年份:
    2005
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Regulation of cell cycle progression by ganglioside-a novel strategy against malignant glioma
神经节苷脂调节细胞周期进程——对抗恶性胶质瘤的新策略
  • 批准号:
    13671434
  • 财政年份:
    2001
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

GLIOMATCH: The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomics
GLIOMATCH:恶性胶质瘤免疫肿瘤学媒人:利用空间分辨的放射多组学实现数据驱动的精准医学
  • 批准号:
    10113516
  • 财政年份:
    2024
  • 资助金额:
    $ 2.3万
  • 项目类别:
    EU-Funded
Self-Assembling Camptothecin Nanofiber Hydrogels as Adjunct Therapy for Intraoperative Treatment of Malignant Glioma
自组装喜树碱纳米纤维水凝胶作为恶性胶质瘤术中治疗的辅助疗法
  • 批准号:
    10738545
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
Retrospective prognostic analysis based on molecular information of malignant glioma and malignant meningioma treated with BNCT
基于BNCT治疗恶性胶质瘤和恶性脑膜瘤分子信息的回顾性预后分析
  • 批准号:
    23K19519
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Elucidating the Role of the Gut and Tumor Microbiome in Malignant Glioma
阐明肠道和肿瘤微生物组在恶性胶质瘤中的作用
  • 批准号:
    10573534
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.
抑制野生型 IDH1 作为治疗恶性神经胶质瘤的铁死亡诱导治疗方法。
  • 批准号:
    10539153
  • 财政年份:
    2022
  • 资助金额:
    $ 2.3万
  • 项目类别:
Decoding hyperexcitability in malignant glioma
解码恶性神经胶质瘤的过度兴奋
  • 批准号:
    10529810
  • 财政年份:
    2022
  • 资助金额:
    $ 2.3万
  • 项目类别:
Decoding hyperexcitability in malignant glioma
解码恶性神经胶质瘤的过度兴奋
  • 批准号:
    10666662
  • 财政年份:
    2022
  • 资助金额:
    $ 2.3万
  • 项目类别:
The establishment of drug-delivery system and the 3D-microimaging of intra-cerebral pharmacokinetics in malignant glioma
恶性胶质瘤给药系统的建立及脑内药动学的3D显微成像
  • 批准号:
    21K15554
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Targeting PARG in malignant glioma therapy
恶性胶质瘤治疗中的靶向 PARG
  • 批准号:
    21K16630
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
IGSF3 promotes tumor progression through synaptic remodeling and hyperexcitability in malignant glioma
IGSF3通过恶性神经胶质瘤的突触重塑和过度兴奋促进肿瘤进展
  • 批准号:
    10315147
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了